Fatty Liver Disease

 

Interesting article

The Influence of Dietary Fat on Liver Fat Accumulation

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4245577/

Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease

The potential sources of fats contributing to fatty liver  include peripheral fats stored in adipose tissue that flow to the liver by way of the plasma NEFA pool (pathway 1); fatty acids newly made within the liver through de novo lipogenesis (DNL) (pathway 2); and dietary fatty acids, which can enter the liver by two means: through spillover into the plasma NEFA pool  (pathway 3) and through the uptake of intestinally derived chylomicron remnants  (pathway 4).

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1087172/

How Fat moves from intestine to adipose tissues

Mechanisms of chylomicron uptake into lacteals

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3132563/

Cholesterol and Triglycerides - Information

High cholesterol in legs - Symptoms

https://timesofindia.indiatimes.com/life-style/health-fitness/health-news/high-cholesterol-signs-of-dangerously-high-cholesterol-levels-present-in-your-legs/photostory/86712234.cms  

Reduction of LDL Cholesterol by 25% to 60% in Patients With Primary Hypercholesterolemia by Atorvastatin, a New HMG-CoA Reductase Inhibitor.

James W. Nawrocki, Stuart R. Weiss, Michael H. Davidson, Dennis L. Sprecher, Sherwyn L. Schwartz, Paul-J. Lupien, Peter H. Jones, Harry E. Haber and Donald M. Black.

Originally published1 May 1995https://doi.org/10.1161/01.ATV.15.5.678Arteriosclerosis, Thrombosis, and Vascular Biology. 1995;15:678–682

Arteriosclerosis, Thrombosis, and Vascular Biology Vol. 15, No. 5

https://www.ahajournals.org/doi/full/10.1161/01.atv.15.5.678

Rosuvastatin for lowering lipids

50% reduction in LDL is reported in multiple studies.

Stephen P Adams, Sarpreet S Sekhon, and James M Wrightcorresponding author

Cochrane Database Syst Rev. 2014 Nov; 2014(11): CD010254. Published online 2014 Nov 21.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6463960/

Who Needs Cholesterol-lowering Medicine

Your treatment plan for high cholesterol will depend on your current cholesterol levels and your risk of heart disease and stroke. Your risk for heart disease and stroke depends on other risk factors, including high blood pressure and high blood pressure treatment, smoking status, age, high-density lipoprotein cholesterol level, total cholesterol level, diabetes, family history, and whether you have already had a heart attack or stroke.

Your health care provider may prescribe medicine if:

You have already had a heart attack or stroke, or you have peripheral arterial disease.

Your LDL cholesterol level is 190 mg/dL or higher.

You are 40–75 years old with diabetes and an LDL cholesterol level of 70 mg/dL or higher.

You are 40–75 years old with a high risk of developing heart disease or stroke and an LDL cholesterol level of 70 mg/dL or higher.

https://www.cdc.gov/cholesterol/treating_cholesterol.htm

Efficacy of alternate day versus everyday dosing of rosuvastatin in hyperlipidemia.

Alternate day gives same effect as daily dose

Chandrashekar Panchavarthi, Ushasree Takkela Shankara, Vijayakrishna Pakanati, Shirisha Siddamshetty, Jaya Prakash Konda, Sai kumar Gowlikar

https://dx.doi.org/10.18203/2319-2003.ijbcp20163234

Published: 2017-01-10

https://www.ijbcp.com/index.php/ijbcp/article/view/635

Fat Cells

https://en.wikipedia.org/wiki/Adipocyte

https://journals.physiology.org/doi/full/10.1152/ajpregu.00257.2017

Ud. 24.9.2022

Pub 5.10.2021